[1] MALLAL S, NOLAN D, WITT C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir[J]. Lancet, 2002, 359(9308):727-732.
[2] KANG H R, JEE Y K, KIM Y S, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans[J]. Pharmacogenet Genom, 2011, 21(5):303-307.
[3] HUNG S L, CHUNG W H, LIOU L B, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol[J]. Proc Nat Acad Sci, 2005, 102(17):6237-6237.
[4] TASSANEEYAKUL W, JANTARAROUNGTONG T, CHEN P, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population[J]. Pharmacogenet Genom, 2009, 19(9):704-709.
[5] KANIWA N, SAITO Y, AIHARA M, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis[J]. Pharmacogenomics, 2008, 9(11):1617-1622.
[6] LONJOU C, BOROT N, SEKULA P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs[J]. Pharmacogenet Genom, 2008, 18(2):99-107.
[7] GENIN E, CHEN D P, HUNG S I, et al. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and Meta-analysis[J]. Pharmacogenomics, 2014, 14(3):281-288.
[8] HETHERINGTON S, HUGHES A R, MOSTELLER M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir[J]. Lancet, 2002, 359(9312):1121-1122.
[9] MARTIN A M, NOLAN D, GAUDIERI S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant[J]. Proc Natl Acad Sci USA, 2004, 101(12):4180-4185.
[10] LUCENA M I, MOLOKHIA M, SHEN Y, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles[J]. Gastroenterology, 2011, 141(1):338-347.
[11] STEPHENS C, LOPEZ-NEVOT M A, RUIZ-CABELLO F, et al. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity[J]. PLoS One, 2013, 8(7):e68111.
[12] ALFIREVIC A, PIRMOHAMED M. Genomics of adverse drug reactions[J]. Trends Pharmacol Sci, 2017, 38(1):100-109.
[13] ZHANG Y, WANG J, ZHAO L M, et al. Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients[J]. Eur J Clin Pharmacol, 2011, 67(9):885-887.
[14] WU X T, HU F Y, AN D M, et al. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China[J]. Epilepsy Behav, 2010, 19(3):405-408.
[15] HUNG S L, CHUNG W H, JEE S H, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions[J]. Pharmacogenet Genom, 2006, 16(4):297-306.
[16] KULKANTRAKORN K, TASSANEEYAKUL W, TIAMKAO S, et al. HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain[J]. Pain Pract, 2012, 12(3):202-208.
[17] CHANG C C, TOO C, MURAD S, et al. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population[J]. Int J Dermatol, 2011, 50(2):221-224.
[18] LOCHARERNKUL C, LOPLUMLERT J, LIMOTAI C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population[J]. Epilepsia, 2008, 49(12):2087-2091.
[19] MEHTA T Y, PRAJAPATI L M, MITTAL B, et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians[J]. Indian J Dermatol VE, 2009, 75(6):579-582.
[20] KANIWA N, SAITO Y, AIHARA M, et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients[J]. Epilepsia, 2010, 51(12):2461-2465.
[21] KIM S H, LEE K W, SONG W J, et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans[J]. Epilepsy Res, 2011, 97(1-2):190-197.
[22] MCCORMACK M, ALFIREVIC A, BOURGEOIS S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans[J]. N Engl J Med, 2011, 364(12):1134-1143.
[23] OZEKI T, MUSHIRODA T, YOWANG A, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population[J]. Hum Mol Genet, 2011, 20(5):1034-1041.
[24] ZHANG F R, LIU H, IRWANTO A, et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome[J]. N Engl J Med, 2013, 369(17):1620-1628.
[25] DALY A K, DONALDSON P T, BHATNAGAR P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin[J]. Nat Genet, 2009, 41(7):816-819.
[26] HUNG S L, CHUNG W H, LIU Z S, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese[J]. Pharmacogenomics, 2010, 11(3):349-356.
[27] FRICKE-GALINDO I, MARTINEZ-JUAREZ I E, MONROY-JARAMILLO N, et al. HLA-A*02:01:01/-B*35:01:01/-C*04:01:01 haplotype associated with lamotrigine-induced maculopapular exanthema in Mexican Mestizo patients[J]. Pharmacogenomics, 2014, 15(15):1881-1891.
[28] SHI Y W, MIN F L, LIU X R, et al. HLA-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population[J]. Basic Clin Pharmacol Toxicol, 2011, 109(1):42-46.
[29] KIM S H, KIM M, LEE K W, et al. HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis[J]. Pharmacogenomics, 2010, 11(6):879-884.
[30] YANG F, XUAN J, CHEN J, et al. HLA-B*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese[J]. Pharmacogenomics, 2016, 16(1):83-87.
[31] CARR D F, CHAPONDA M, JORGENSEN A L, et al. Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population[J]. Clin Infect Dis, 2013, 56(9):1330-1339.
[32] YUAN J, GUO S, HALL D, et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent[J]. AIDS, 2011, 25(10):1271-1280.
[33] KEANE N M, PAVLOS R K, MCKINNON E, et al. HLA class Ⅰ restricted CD8⁺ and class Ⅱ restricted CD4⁺ T cells are implicated in the pathogenesis of nevirapine hypersensitivity[J]. AIDS, 2014, 28(13):1891-1901.
[34] CHANTARANGSU S, MUSHIRODA T, MAHASIRIMONGKOL S, et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients[J]. Pharmacogenet Genom, 2009, 19(2):139-146.
[35] CHEN C B, HSIAO Y H, WU T, et al. Risk and association of HLA with oxcarbazepineinduced cutaneous adverse reactions in Asians[J]. Neurology, 2017, 88(1):78-86.
[36] MAN C B, KWAN P, BAUM L, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese[J]. Epilepsia, 2007, 48(5):1015-1018.
[37] HARDING D J, SUBRAMANIAM K, MACQUILLAN G, et al. Severe drug-induced hypersensitivity syndrome with a shared HLA-B allele[J]. Med J Aust, 2012, 197(7):411-413.
[38] TASSANEEYAKUL W, PRABMEECHAI N, SUKASEM C, et al. Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population[J]. Pharmacogenet Genom, 2016, 26(5):225-234.
[39] LONJOU C, BOIOT N, SEKULA P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs[J]. Pharmacogenet Genom, 2008, 18(2):99-107.
[40] ROBINSON J, HALLIWELL J A, HAYHURST J D, et al. The IPD and IMGT/HLA database: allele variant databases[J]. Nucleic Acids Res, 2015, 43(D1):D423-D431.
[41] LANDSTEINER K, JACOBS J. Studies on the sensitization of animals with simple chemical compounds[J]. J Exp Med, 1935, 61(5):643-656.
[42] FAULKNER L, MENG X L, PARK B K, et al. The importance of hapten-protein complex formation in the development of drug allergy[J]. Curr Opin Allergy Clin Immunol, 2014, 14(4):293-300.
[43] JENKINS R E, MENG X, ELLIOTT V L, et al. Characterisation of flucloxacillin and 5-hydroxymethyl flucloxacillin haptenated HSAin vitroand in vivo[J]. Proteomics Clin Appl, 2009, 3(6):720-729.
[44] PICHLER W J, BEELER A, KELLER M, et al. Pharmacological interaction of drugs with immune receptors: the p-i concept[J]. Allergol Int, 2006, 55(1):17-25.
[45] PICHLER W J. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept[J]. Curr Opin Allergy Clin Immunol, 2002, 2(4):301-305.
[46] PICHLER W J. Direct T-cell stimulations by drugs—bypassing the innate immune system[J]. Toxicology, 2005, 209(2):95-100.
[47] CHESSMAN D, KOSTENKO L, LETHBORG T, et al. Human leukocyte antigen class I-restricted activation of CD8⁺ T cells provides the immunogenetic basis of a systemic drug hypersensitivity[J]. Immunity, 2008, 28(6):822-832.
[48] YUN J, MATTSSON J, SCHNYDER K, et al. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response[J]. Clin Exp Allergy, 2013, 43(11):1246-1255.
[49] WUILLEMIN N, ADAM J, FONTANA S, et al. HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin[J]. J Immunol, 2013, 190(10):4956-4964.
[50] NORCROSS M A, LUO S, LU L, et al. Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity[J]. AIDS, 2012, 26(11):F21-29.
[51] PICHLER W J, ADAM J, WATKINS S, et al. Drug hypersensitivity: how drugs stimulate T cells via pharmacological interaction with immune receptors[J]. Int Arch Allergy Immunol, 2015, 168(1):13-24.
[52] ILLING P T, VIVIAN J P, DUDEK N L, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire[J]. Nature, 2012, 486(7404):554-558.
[53] OSTROV D A, GRANT B J, POMPEU Y A, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire[J]. Proc Natl Acad Sci USA, 2012, 109(25):9959-9964.
[54] UNUTMAZ D, ADAM J, WUILLEMIN N, et al. Abacavir induced T cell reactivity from drug naïve individuals shares features of allo-immune responses[J/OL]. PLoS One, 2014, 9(4) [2014-04-21]. 10.1371/journal.pone.0095339.
[55] HIRASAWA M, HAGIHARA K, OKUDAIRA N, et al. The possible mechanism of idiosyncratic lapatinib-induced liver injury in patients carrying human leukocyte antigen-DRB1*07:01[J/OL]. PLoS One, 2015, 10(6)[2015-06-22]. 10.1371/journal.pone.0130928.
[56] HIRASAWA M, HAGIHARA K, ABE K, et al. In silico and in vitro analysis of interaction between ximelagatran and human leukocyte antigen (HLA)-DRB1*07:01[J]. Int J Mol Sci, 2017, 18(4):694.
[57] METUSHI I G, WRISTON A, BANERJEE P, et al. Acyclovir has low but detectable influence on HLA-B*57:01 specificity without inducing hypersensitivity[J]. PLoS One, 2015, 10(5)[2015-05-29]. 10.1371/journal.pone.0124878.
[58] KO T M, CHUNG W H, WEI C Y, et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome[J]. J Allergy Clin Immunol, 2011, 128(6):1266-1276.
[59] WATKINS S, PICHLER W J. Sulfamethoxazole induces a switch mechanism in T cell receptors containing TCRVbeta20-1, altering pHLA recognition[J/OL]. PLoS One, 2013, 8(10) [2013-10-07]. 10.1371/journal.pone.0076211.
[60] ZHOU P, ZHANG S, WANG Y, et al. Structural modeling of HLA-B*1502/peptide/carbamazepine/T-cell receptor complex architecture: implication for the molecular mechanism of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis[J]. J Biomol Struct Dyn, 2016, 34(8):1806-1817.
[61] WHITE K D, ABE R, ARDERN-JONES M, et al. SJS/TEN 2017: building multidisciplinary networks to drive science and translation[J]. J Allergy Clin Immunol Pract, 2018, 6(1):38-69.
[62] CAUDLE K E, RETTIE A E, WHIRL-CARRILLO M, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing[J]. Clin Pharmacol Ther, 2014, 96(5):542-548.
[63] CHUNG W H, CHANG W C, LEE Y S, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions[J]. JAMA, 2014, 312(5):525-534.
[64] CARR D F, BOURGEOIS S, CHAPONDA M, et al. Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population[J]. J Antimicrob Chemother, 2017, 72(4):1152-1162.
[65] KENNA T J, ROBINSON P C, HAROON N. Endoplasmic reticulum aminopeptidases in the pathogenesis of ankylosing spondylitis[J]. Rheumatology, 2015, 54(9):1549-1556.
[66] LUCAS A, LUCAS M, STRHYN A, et al. Abacavir-reactive memory T cells are present in drug naive individuals[J/OL]. PLoS One, 2015, 10(2)[2015-02-12]. 10.1371/journal.pone.0117160.
[67] HETHERINGTON S, MCGUIRK S, POWELL G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir [J]. Clin Therap, 2001, 23(10):1603-1614.
[68] ARROYO S, DE LA MORENA A. Life-threatening adverse events of antiepileptic drugs[J]. Epilepsy Res, 2001, 47(1-2):155-174.
[69] PICHLER W, YAWALKAR N, SCHMID S, et al. Pathogenesis of drug-induced exanthems[J]. Allergy, 2002, 57(10):884-893.
[70] WHITE K D, CHUNG W H, HUNG S I, et al. Evolving models of the immunopathogenesis of T cell-mediated drug allergy: the role of host, pathogens, and drug response[J]. J Allergy Clin Immunol, 2015, 136(2):219-234.
[71] DUONG T A, VALEYRIE-ALLANORE L, WOLKENSTEIN P, et al. Severe cutaneous adverse reactions to drugs[J]. Lancet, 2017, 390(10106):1996-2011.
[72] PARA O, CRISPINO P, BARONE N, et al. Sex differences in adverse drug reaction and liver disease[J]. Italian J Med, 2018, 12(1):15.
[73] HORNBERG J J, LAURSEN M, BRENDEN N, et al. Exploratory toxicology as an integrated part of drug discovery. Part I: why and how[J]. Drug Discov Today, 2014, 19(8):1131-1136.
[74] ARROWSMITH J, MILLER P. Trial watch: phase Ⅱ and phase Ⅲ attrition rates 2011-2012[J]. Nat Rev Drug Discov, 2013, 12(8):569.
[75] SWINNEY D C, ANTHONY J. How were new medicines discovered?[J]. Nat Rev Drug Discov, 2011, 10(7):507-519.
[76] BERG E L, HSU Y C, LEE J A. Consideration of the cellular microenvironment: physiologically relevant co-culture systems in drug discovery[J]. Adv Drug Deliv Rev, 2014, 69-70:190-204.
[77] HOUCK K A, KAVLOCK R J. Understanding mechanisms of toxicity: insights from drug discovery research[J]. Toxicol Appl Pharmacol, 2008, 227(2):163-178.
[78] BERG E L, YANG J, MELROSE J, et al. Chemical target and pathway toxicity mechanisms defined in primary human cell systems[J]. J Pharmacol Toxicol Methods, 2010, 61(1):3-15.
[79] XU J J, HENSTOCK P V, DUNN M C, et al. Cellular imaging predictions of clinical drug-induced liver injury[J]. Toxicol Sci, 2008, 105(1):97-105.
[80] IVANOV S M, LAGUNIN A A, POROIKOV V V. In silico assessment of adverse drug reactions and associated mechanisms[J]. Drug Discov Today, 2016, 21(1):58-71.
[81] NICOLETTI P, AITHAL G P, BJORNSSON E S, et al. Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study[J]. Gastroenterology, 2017, 152(5):1078-1089.
[82] KARNES J H, SHAFFER C M, BASTARACHE L, et al. Comparison of HLA allelic imputation programs[J/OL]. PLoS One, 2017, 12(2) [2017-02-16]. 10. 1371/journal. pone. 0172444.
[83] VAN DEN DRIESSCHE G, FOURCHES D. Adverse drug reactions triggered by the common HLA-B*57:01 variant: a molecular docking study[J]. J Cheminform, 2017, 9(13) [2017-03-04]. 10.1186/s13321-017-0202-6.
[84] WEI C Y, CHUNG W H, HUANG H W, et al. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome[J]. J Allergy Clin Immunol, 2012, 129(6):1562-1569.
[85] LUO H, DU T T, ZHOU P, et al. Molecular docking to identify associations between drugs and class I human leukocyte antigens for predicting idiosyncratic drug reactions[J]. Combin Chem High Through Screen, 2015, 18(3):296-304.